Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on PROCEPT BioRobotics. The associated price target is $83.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mike Kratky has given his Buy rating due to a combination of factors that highlight the potential for growth and stability in PROCEPT BioRobotics’ performance. The company reported a 4% sales beat in the second quarter of 2025, driven by higher average selling prices in the U.S. and strong international momentum. Despite a softer third-quarter guidance, the full-year sales guidance was slightly raised, and the gross margin guidance was improved, indicating a positive outlook for the remainder of the year.
Additionally, Kratky sees several growth drivers for the company, including the ongoing launch of the HYDROS system and potential upside in the average selling price guidance for the second half of the year. Longer-term catalysts such as a robust replacement cycle expected in fiscal year 2026 and increased regulatory visibility into the prostate cancer market further support the Buy rating. The company’s historically undemanding valuation also adds to the attractiveness of the stock, making it a compelling investment opportunity.
Kratky covers the Healthcare sector, focusing on stocks such as NeuroPace, Medtronic, and Intuitive Surgical. According to TipRanks, Kratky has an average return of 7.0% and a 39.23% success rate on recommended stocks.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $55.00 price target.